Portage Biotech (PRTG) Stock Price, News & Analysis

Company Overview

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Key Stats

• Today's Range: $4.21 to $4.70
• 50-Day Range: $3.56 to $10.21
• 52-Week Range: $2.10 to $40.80
• Volume: 51,151 shs
• Average Volume: 525,140 shs
• Market Capitalization: $4.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $120.00
• Consensus Rating: Hold

Portage Biotech Stock Analysis - MarketRank™

Portage Biotech scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Portage Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Portage Biotech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Portage Biotech are expected to grow in the coming year, from ($13.00) to ($10.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Portage Biotech is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Portage Biotech is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Portage Biotech has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.42% of the float of Portage Biotech has been sold short.

Short Interest Ratio / Days to Cover

Portage Biotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Portage Biotech has recently decreased by 22.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Portage Biotech does not currently pay a dividend.

Dividend Growth

Portage Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.42% of the float of Portage Biotech has been sold short.

Short Interest Ratio / Days to Cover

Portage Biotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Portage Biotech has recently decreased by 22.87%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Portage Biotech this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for PRTG on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Portage Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.36% of the stock of Portage Biotech is held by institutions.

PRTG Stock Analysis - Frequently Asked Questions

How have PRTG shares performed this year?

Portage Biotech's stock was trading at $36.40 at the start of the year. Since then, PRTG shares have decreased by 87.3% and is now trading at $4.62.
View the best growth stocks for 2024 here.

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) released its quarterly earnings results on Tuesday, August, 27th. The company reported ($1.58) earnings per share (EPS) for the quarter.

When did Portage Biotech's stock split?

Portage Biotech shares reverse split on Thursday, August 15th 2024. The 1-20 reverse split was announced on Tuesday, August 13th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Portage Biotech's major shareholders?

Top institutional shareholders of Portage Biotech include Virtu Financial LLC (1.04%).

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Portage Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Portage Biotech investors own include Meta Platforms (META), Alimera Sciences (ALIM), Angion Biomedica (ANGN), AirNet Technology (ANTE), Broadcom (AVGO), Barnwell Industries (BRN) and Catalyst Biosciences (CBIO).

Company Calendar

• Last Earnings: 8/27/2024
• Today: 11/21/2024
• Next Earnings (Estimated): 11/26/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRTG
• CUSIP: N/A
• CIK: 1095435
• Web: www.portagebiotech.com
• Phone: 416-929-1806
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $120.00
• High Stock Price Target: $120.00
• Low Stock Price Target: $120.00
• Potential Upside/Downside: +2,497.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($46.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-75,340,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -137.65%
• Return on Assets: -92.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.73
• Quick Ratio: 1.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $9.06 per share
• Price / Cash Flow: 0.51
• Book Value: $3.74 per share
• Price / Book: 1.24

Miscellaneous

• Outstanding Shares: 1,050,000
• Free Float: 608,000
• Market Cap: $4.85 million
• Optionable: Optionable
• Beta: 1.59